Form 4: Pulse Biosciences CTO Sells Shares Under Pre-Arranged Trading Plan

Pulse Biosciences' Chief Technology Officer and Director, Darrin Uecker, sold a total of 30,000 shares of common stock over two days in June 2025, pursuant to a Rule 10b5-1 trading plan.

Summary

• Darrin Uecker, Chief Technology Officer and Director of Pulse Biosciences, Inc. (PLSE), reported the sale of common stock.
• On June 12, 2025, Mr. Uecker sold 15,000 shares of common stock at a weighted average price of $16.4 per share, with prices ranging from $16.32 to $16.57.
• On June 13, 2025, an additional 15,000 shares were sold at a weighted average price of $15.98 per share, with prices ranging from $15.90 to $16.04.
• These transactions were conducted under a Rule 10b5-1(c) pre-arranged trading plan.
• Following these sales, Mr. Uecker directly beneficially owns 122,872 shares of Pulse Biosciences common stock.
• The total value of shares sold across both transactions amounts to approximately $485,700.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly negative. While insider selling can be perceived negatively, the fact that it was conducted under a Rule 10b5-1 plan mitigates concerns about opportunistic selling based on non-public information, making it a pre-planned event rather than a reactive one.

Positives

• The transactions were executed under a Rule 10b5-1 trading plan, indicating they were pre-scheduled and not based on immediate non-public information, which can reduce concerns about opportunistic insider selling.

Negatives

• Insider selling, even when pre-arranged, reduces the direct ownership stake of a key executive and director, which some investors may interpret as a slight reduction in conviction.
• The sales occurred over two consecutive days, totaling a significant number of shares (30,000).

Risks

• While executed under a 10b5-1 plan, significant insider selling can sometimes be perceived negatively by the market, potentially leading to short-term share price volatility if investors misinterpret the nature of the sale.

Future Outlook

The document is an SEC Form 4 filing, which reports insider transactions and does not contain forward-looking statements or guidance regarding the company's future performance or strategic outlook.

Management Comments

• The Reporting Person undertakes upon request by the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares sold at each separate price within the reported range.

Industry Context

This Form 4 filing details an individual insider stock transaction and does not provide information relevant to broader industry trends or competitive landscape analysis. It is specific to the reporting person and Pulse Biosciences.

Comparison to Industry Standards

• Not applicable. This document reports an individual insider stock transaction and does not contain company performance metrics or operational results that can be compared to industry benchmarks or specific comparable companies/projects.

Corporate Governance

Stakeholder Impact

• Shareholders: May view the reduction in insider ownership as a slight negative, though the 10b5-1 plan mitigates concerns about the timing of the sale.
• Employees: No direct impact mentioned.

Next Steps

• The Reporting Person has undertaken to provide full information regarding the number of shares sold at each separate price within the reported range upon request by the SEC staff, the Issuer, or a security holder of the Issuer.

Key Dates

Recommendation

Keywords

Pulse Biosciences, PLSE, Darrin Uecker, Form 4, Insider Trading, Stock Sale, Chief Technology Officer, Director, 10b5-1 Plan, Equity Transaction